MDxHealth (MDXH) Competitors

53.7% of Standard BioTools shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MDxHealth has a net margin of -31.07% compared to Standard BioTools' net margin of -59.39%. Standard BioTools' return on equity of -11.21% beat MDxHealth's return on equity.

MDxHealth has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

In the previous week, Standard BioTools had 4 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Standard BioTools and 1 mentions for MDxHealth. Standard BioTools' average media sentiment score of 0.93 beat MDxHealth's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the news media.

MDxHealth currently has a consensus price target of $7.75, indicating a potential upside of 287.50%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 37.90%. Given MDxHealth's stronger consensus rating and higher probable upside, research analysts clearly believe MDxHealth is more favorable than Standard BioTools.

MDxHealth has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MDxHealth has a net margin of -31.07% compared to SOPHiA GENETICS's net margin of -44.22%. SOPHiA GENETICS's return on equity of -50.60% beat MDxHealth's return on equity.

SOPHiA GENETICS has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

In the previous week, SOPHiA GENETICS had 8 more articles in the media than MDxHealth. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 1 mentions for MDxHealth. SOPHiA GENETICS's average media sentiment score of 0.45 beat MDxHealth's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

SOPHiA GENETICS currently has a consensus price target of $7.50, indicating a potential upside of 47.93%. MDxHealth has a consensus price target of $7.75, indicating a potential upside of 287.50%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than SOPHiA GENETICS.

MDxHealth has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Zepp Health has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

Zepp Health has a net margin of -15.48% compared to MDxHealth's net margin of -31.07%. Zepp Health's return on equity of -15.00% beat MDxHealth's return on equity.

In the previous week, Zepp Health and Zepp Health both had 1 articles in the media. Zepp Health's average media sentiment score of 1.93 beat MDxHealth's score of 0.00 indicating that Zepp Health is being referred to more favorably in the media.

52.6% of Zepp Health shares are owned by institutional investors. 36.0% of Zepp Health shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MDxHealth has lower revenue, but higher earnings than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Zepp Health presently has a consensus price target of $56.28, suggesting a potential upside of 219.95%. MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 287.50%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Zepp Health.

KORU Medical Systems has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

KORU Medical Systems has a net margin of -6.41% compared to MDxHealth's net margin of -31.07%. KORU Medical Systems' return on equity of -15.90% beat MDxHealth's return on equity.

In the previous week, KORU Medical Systems had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for KORU Medical Systems and 1 mentions for MDxHealth. KORU Medical Systems' average media sentiment score of 0.34 beat MDxHealth's score of 0.00 indicating that KORU Medical Systems is being referred to more favorably in the media.

58.6% of KORU Medical Systems shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

KORU Medical Systems has higher earnings, but lower revenue than MDxHealth. KORU Medical Systems is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

KORU Medical Systems presently has a consensus price target of $6.50, suggesting a potential upside of 59.31%. MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 287.50%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than KORU Medical Systems.